Clinical Trial Update: Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating interleukin-15 in combination with avelumab in relapsed/refractory mature T-cell malignancies completed; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Mycosis Fungoides
• Peripheral T-cell Lymphoma Nos
• Sezary Syndrome

Drugs mentioned

• Avelumab (avelumab)
• Interleukin-15 (IL-15) (interleukin-15)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Peripheral T-cell Lymphoma NOS, Mycosis Fungoides | Phase 1 | Status: COMPLETED | Results posted: 2022-09-13